Home › Targets › JAK3

JAK3 (1 companies · 3 programs)

Companies with an active program directed at JAK3.

Aclaris Therapeutics ACRS

ATI-2138 — Atopic Dermatitis Phase 2
lepzacitinib — Atopic Dermatitis
ATI-2138 — Lichen Planus Phase 2